Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Prospective, Parallel Group, Placebo-Controlled, Multi-Center Study on the Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence

NCT00376272 is registered in ClinicalTrials.gov with Gruppo di Ricerca GISSI as lead sponsor.

NCT NCT00376272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00376272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Prospective, Parallel Group, Placebo-Controlled, Multi-Center Study on the Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence
Lead sponsor
Gruppo di Ricerca GISSI
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2004
Completion date
March 31, 2008
Enrollment
1,442 (actual)
Sites
114

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation